Regions Financial Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$581K Buy
1,300
+191
+17% +$89.1K ﹤0.01% 573
2025
Q4
$503K Buy
1,109
+462
+71% +$199K ﹤0.01% 606
2025
Q3
$253K Sell
647
-90
-12% -$37.6K ﹤0.01% 764
2025
Q2
$328K Buy
737
+30
+4% +$13.8K ﹤0.01% 690
2025
Q1
$343K Buy
707
+51
+8% +$23.8K ﹤0.01% 659
2024
Q4
$264K Sell
656
-352
-35% -$163K ﹤0.01% 727
2024
Q3
$469K Sell
1,008
-16
-2% -$7.69K ﹤0.01% 603
2024
Q2
$480K Buy
1,024
+270
+36% +$117K ﹤0.01% 584
2024
Q1
$315K Buy
754
+54
+8% +$22.8K ﹤0.01% 690
2023
Q4
$285K Sell
700
-565
-45% -$209K ﹤0.01% 715
2023
Q3
$440K Sell
1,265
-10
-0.8% -$3.5K ﹤0.01% 589
2023
Q2
$449K Sell
1,275
-28
-2% -$9.43K ﹤0.01% 603
2023
Q1
$411K Sell
1,303
-62
-5% -$18.6K ﹤0.01% 634
2022
Q4
$394K Sell
1,365
-2
-0.1% -$610 ﹤0.01% 638
2022
Q3
$396K Sell
1,367
-392
-22% -$113K ﹤0.01% 619
2022
Q2
$495K Sell
1,759
-307
-15% -$82.2K ﹤0.01% 595
2022
Q1
$539K Sell
2,066
-952
-32% -$226K ﹤0.01% 609
2021
Q4
$663K Sell
3,018
-1,346
-31% -$262K 0.01% 576
2021
Q3
$791K Sell
4,364
-7,668
-64% -$1.5M 0.01% 522
2021
Q2
$2.43M Sell
12,032
-53,803
-82% -$11.3M 0.02% 329
2021
Q1
$14.1M Sell
65,835
-7,951
-11% -$1.75M 0.13% 136
2020
Q4
$17.4M Sell
73,786
-270
-0.4% -$61.9K 0.17% 123
2020
Q3
$20.2M Buy
74,056
+5,750
+8% +$1.59M 0.22% 106
2020
Q2
$19.8M Buy
68,306
+6,911
+11% +$1.87M 0.23% 105
2020
Q1
$14.6M Sell
61,395
-1,469
-2% -$337K 0.19% 120
2019
Q4
$13.8M Sell
62,864
-182
-0.3% -$36.8K 0.14% 138
2019
Q3
$10.7M Buy
63,046
+4,401
+8% +$779K 0.12% 147
2019
Q2
$10.8M Buy
58,645
+12,672
+28% +$2.22M 0.12% 144
2019
Q1
$8.46M Buy
45,973
+44,231
+2,539% +$8.17M 0.1% 157
2018
Q4
$288K Sell
1,742
-2,107
-55% -$365K ﹤0.01% 652
2018
Q3
$742K Sell
3,849
-1,036
-21% -$184K 0.01% 471
2018
Q2
$831K Sell
4,885
-2,158
-31% -$335K 0.01% 457
2018
Q1
$1.15M Sell
7,043
-2,526
-26% -$413K 0.01% 401
2017
Q4
$1.43M Sell
9,569
-1,778
-16% -$263K 0.02% 371
2017
Q3
$1.73M Sell
11,347
-4,135
-27% -$622K 0.02% 326
2017
Q2
$2M Sell
15,482
-76,766
-83% -$9.24M 0.02% 301
2017
Q1
$10.1M Sell
92,248
-18,664
-17% -$1.64M 0.12% 139
2016
Q4
$8.17M Sell
110,912
-5,921
-5% -$482K 0.1% 146
2016
Q3
$10.2M Sell
116,833
-5,351
-4% -$506K 0.13% 132
2016
Q2
$10.5M Buy
122,184
+5,942
+5% +$513K 0.14% 132
2016
Q1
$9.24M Buy
116,242
+10,478
+10% +$948K 0.12% 146
2015
Q4
$13.3M Buy
105,764
+7,030
+7% +$849K 0.18% 124
2015
Q3
$10.3M Buy
98,734
+10,659
+12% +$1.37M 0.15% 138
2015
Q2
$10.9M Buy
88,075
+72,950
+482% +$9.19M 0.14% 143
2015
Q1
$1.78M Buy
15,125
+3,035
+25% +$364K 0.02% 359
2014
Q4
$1.44M Sell
12,090
-278
-2% -$31.3K 0.02% 419
2014
Q3
$1.39M Sell
12,368
-1,002
-7% -$95.4K 0.02% 483
2014
Q2
$1.27M Buy
13,370
+2,986
+29% +$209K 0.02% 520
2014
Q1
$734K Buy
10,384
+1,111
+12% +$88K 0.01% 680
2013
Q4
$689K Buy
+9,273
New +$646K 0.01% 676

Other funds holding VRTX

Regions Financial Corp's VRTX Position: Q1 2026 in Review

Regions Financial Corp increased its Vertex Pharmaceuticals (VRTX) stake by 17% in Q1 2026, buying an estimated $89.1K and bringing the position to 1,300 shares worth $581K. The position accounts for ﹤0.01% of the portfolio, ranked #573.

Regions Financial Corp first reported a position in VRTX in Q4 2013 and has held it in 50 quarters since. The position peaked at $20.2M in Q3 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Regions Financial Corp held 1,300 shares of Vertex Pharmaceuticals worth $581K as of Q1 2026.
  • Regions Financial Corp bought 191 Vertex Pharmaceuticals shares in Q1 2026, an estimated $89.1K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Regions Financial Corp's portfolio in Q1 2026, its #573 holding.
  • Regions Financial Corp first reported a position in Vertex Pharmaceuticals in Q4 2013 and has held it in 50 quarters since.
  • Regions Financial Corp's Vertex Pharmaceuticals position peaked at $20.2M in Q3 2020.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Regions Financial Corp's 13F filing for Q1 2026, filed 5 May 2026.